ESKETamine for FIBromyalgia Treatment

Randomized, sequential interventional study in patients with fibromyalgia evaluating supportive-care use of intravenous S-ketamine at 0.2 mg/kg and 0.4 mg/kg compared with an active comparator (clonidine 1 µg/kg plus magnesium sulfate 40 mg/kg).

Primary objective is supportive care for pain reduction and quality-of-life improvement in fibromyalgia; outcomes include pain measures and clinical safety/tolerability assessments.